Johnson Fistel Investigates Valneva Following FDA Suspension

Core Viewpoint - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Valneva SE regarding possible violations of federal securities laws due to alleged misrepresentations and omissions by the company and its executives [1] Company Developments - On August 25, 2025, Valneva acknowledged that the FDA suspended the license for its chikungunya vaccine Ixchiq, following four reports of serious adverse events, mandating the cessation of all shipping and sale of the vaccine within the United States [3] Legal Context - Investors who purchased Valneva securities and incurred significant losses may be eligible to participate in a potential class action or seek recovery of their losses [2]